RS54752B1 - Triazolopiridini kao inhibitori fosfodiesteraze za lečenje kožnih bolesti - Google Patents
Triazolopiridini kao inhibitori fosfodiesteraze za lečenje kožnih bolestiInfo
- Publication number
- RS54752B1 RS54752B1 RS20160308A RSP20160308A RS54752B1 RS 54752 B1 RS54752 B1 RS 54752B1 RS 20160308 A RS20160308 A RS 20160308A RS P20160308 A RSP20160308 A RS P20160308A RS 54752 B1 RS54752 B1 RS 54752B1
- Authority
- RS
- Serbia
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocycloalkyl
- nr7r8
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Jedinjenje opšte formule I,pri čemu R1 je C1-6 alkoksi, kao što su metoksi, mono-, di- ili trifluormetoksi, haiogen, ili hidroksi;R2 je alkil, cikloalkil, alkilcikloalkil, ili cikloalkil (C(O)NR7R8), od kojih je svaki opciono supstituisan sa jednim ili više supstituenata izabranih između R4;R3 je vodonik, halogen, aril, hetercaril, hidroksi, alkil, cikloalkil, heterocikloalkil, alkoksi, okso, cijano, amino, aminoalkil, alkilamino ili dialkilamino;R4je vodonik, halogen, hidroksi, okso, cijano, karboksi, ili trihalometil, ili R4 je NR5R6, -C(O)NR7R8, -C(O)R7, -COOR7, -NR5C(O)NR7R8, -OC(O)NR7R8, -OC(O)R3, NC(O)R7, -OR7, -NC(O)OR3, -NSO2R7, -SO2NR7R8, ili -SO2R7R8, alkil, cikloalkil, alkenil, alkinil, aril, heteroaril, cikloalkilalkil, cikloalkilalkenil, cikloalkilalkinil, cikloalkenilalkil, cikloalkenilalkenil, cikloalkenilalkinil, heterocikloalkil, heterocikloalkilalkil, heterocikioalkenil, heterocikloalkenilalkil, heterocikloalkenilalkenil, heterocikloalkenilalkinil, arilalkil, arilalkenil, arilalkinil, heteroariialkil, heteroarilalkenil, heteroarilalkinil, alkoksi, cikloalkiloksi, alkiltio, cikloalkiltio, sulfamoil, sulfinamoil, alkilamino ili cikloalkilamino, od kojih je svaki opciono supstituisan sa jednim ili više supstituenata izabranih između R9;svaki R5 i R6 nezavisno predstavlja vodonik, alkil, alkenil, cikloalkil, heterocikloalkil, -C(O)alkil, -C(O)Oalkil, -C(O)cikloalkil, -C(O)N-alkil, karboksialkil, -C(O)alkil-C(O)OH, -C(O)alkil-C(O)N-alkil, -C(O)N-aril, -S(O)2alkil, -S(O)alkil, -S(O)2aril, -S(O)2N-alkil, -S(O)aril, aril, heteroaril alkilaril ili alkilheteroaril, od kojih je svaki opciono supstituisan sa hidroksi ili jednim ili više halogena, ili R5 i R6 zajedno sa atomom azota za koji su vezani obrazuju heterocikloalkil prsten. pri čemu je pomenuti prsten opciono supstituisan sa jednom ili više alkil grupa; svaki R7 i R8 nezavisno predstavlja vodonik, alkil, cikloalkil, alkenil, heteroaril, heterocikloalkil, karboksialkil, karbamoilalkil, alkiloksialkil, alkeniloksialkil, aril, arilalkil, alkilaril, heteroaril, heteroarilalkil, ili alkilheteroaril, od kojih je svaki opciono supstituisan sa jednim ili više supstituenata izabranih iz grupe koju čine hidroksi, halogen, okso, cijano, alkil, cikloalkil, alkenil, alkoksi, aril, heteroaril, heterocikloalkil, -S(O)2-alkil, -S(O)2-NR11R12, -NC(O)-alkil, -C(O)N-alkil, -NC(O)O-alkil, -OC(O)N-alkil, -NC(O)NR11R12, -NR11SO2-alkil, -S(O)-alkil, iii R7 i R8 zajedno sa atomom azota za koji su vezani obrazuju heterocikloalkil prsten, pri čemu je pomenuti prsten opciono supstituisan sa jednom ili više alkil grupa;R9 je vodonik, halogen, hidroksi, alkoksi, karboksi ili trihalometil;X i Y su ili C i N ili N i C, respektivno;A je aril, cikloalkil, cikloalkenil, heteroaril, heterocikloalkil ili heterocikioalkenil, od kojih je svaki opciono supstituisan sa jednim ili više supstituenata izabranih iz grupe koja se sastoji od R10;R10 je vodonik, cijano, halogen, hidroksi, ili okso, ili je R10 alkil, cikloalkil, alkenil, alkinil, aril, heteroaril, cikloalkilalkil. cikloalkilalkenil, cikloalkilaikinil, cikloalkenilalkil, cikloalkenilalkenil, cikloalkenilalkinil, heterocikloalkil, heterocikloalkenil, heterocikloalkenilalkil, heterocikloalkenilalkenil, heterocikloalkenilalkinil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenii, heteroarilalkinil, alkoksi, cikloalkiloksi, alkiltio, cikloalkiltio, -S(O)alkil, -S(O)2-alkil, sulfamoil, sulfinamoil, -C(O)OR3, -C(O)R3, -NR5R6, -alkil(NR5R6), -cikloalkil(NR5R6), -cikloaikilalkil(NR5R6), -alkilcikloalkil(NR5R6), -C(O)NR7R8, -aikil(C(O)NR7R8), -cikloalkil(C(O)NR7R8), -cikloalkilalkil(C(O)NR7R8) ili -alkilcikloalkil(C(O)NR7R8), od kojih je svaki opciono supstituisan sa jednim ili više supstituenata izabranih između R4; R11 i R12 svaki nezavisno predstavlja vodonik ili alkil;i njegove farmaceutski prihvatljive soli, hidrati, N-oksidi ili solvati.Prijava sadrži još 29 patentnih zahteva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13944508P | 2008-12-19 | 2008-12-19 | |
| EP09795687.4A EP2379548B1 (en) | 2008-12-19 | 2009-12-18 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| PCT/DK2009/000262 WO2010069322A1 (en) | 2008-12-19 | 2009-12-18 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54752B1 true RS54752B1 (sr) | 2016-10-31 |
Family
ID=41693461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20160308A RS54752B1 (sr) | 2008-12-19 | 2009-12-18 | Triazolopiridini kao inhibitori fosfodiesteraze za lečenje kožnih bolesti |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8952162B2 (sr) |
| EP (1) | EP2379548B1 (sr) |
| JP (2) | JP5743901B2 (sr) |
| KR (1) | KR20110094355A (sr) |
| CN (1) | CN102317287B (sr) |
| AU (1) | AU2009328752B2 (sr) |
| BR (1) | BRPI0922452A2 (sr) |
| CA (1) | CA2747022A1 (sr) |
| CY (1) | CY1117562T1 (sr) |
| DK (1) | DK2379548T3 (sr) |
| ES (1) | ES2570769T3 (sr) |
| HK (1) | HK1165791A1 (sr) |
| HR (1) | HRP20160488T1 (sr) |
| HU (1) | HUE027770T2 (sr) |
| IL (1) | IL213570A (sr) |
| MX (1) | MX2011006428A (sr) |
| NO (1) | NO20110871A1 (sr) |
| NZ (1) | NZ593595A (sr) |
| PL (1) | PL2379548T3 (sr) |
| RS (1) | RS54752B1 (sr) |
| RU (1) | RU2544011C2 (sr) |
| SG (1) | SG172206A1 (sr) |
| SI (1) | SI2379548T1 (sr) |
| WO (1) | WO2010069322A1 (sr) |
| ZA (1) | ZA201104422B (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| TWI485150B (zh) | 2009-07-17 | 2015-05-21 | Japan Tobacco Inc | 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| WO2011076207A2 (en) | 2009-12-22 | 2011-06-30 | Leo Pharma A/S | Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
| MX2012007225A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. |
| MX2012007234A (es) | 2009-12-22 | 2012-07-30 | Leo Pharma As | Nanocristales de monohidrato de calciprotiol. |
| JP2014511393A (ja) * | 2011-03-07 | 2014-05-15 | セルジーン コーポレイション | イソインドリン化合物を用いた疾患の治療方法 |
| WO2013092739A1 (en) * | 2011-12-21 | 2013-06-27 | Leo Pharma A/S | [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors |
| US9855285B2 (en) * | 2012-11-30 | 2018-01-02 | Leo Pharma A/S | Method of inhibiting the expression of IL-22 in activated T-cells |
| WO2014206903A1 (en) | 2013-06-25 | 2014-12-31 | Leo Pharma A/S | METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| KR102676384B1 (ko) | 2017-06-20 | 2024-06-20 | 유니온 테라퓨틱스 에이/에스 | 1,3-벤조디옥솔 헤테로시클릭 화합물의 제조방법 |
| FI3724196T3 (fi) | 2017-12-15 | 2023-01-31 | Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä | |
| JP2021155336A (ja) * | 2018-06-27 | 2021-10-07 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 新規ｐｄｅ４阻害剤 |
| AR114977A1 (es) | 2018-06-27 | 2020-11-11 | Meiji Seika Pharma Co Ltd | Cristales de derivado de benzoxazol |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU705690B2 (en) | 1995-05-19 | 1999-05-27 | Kyowa Hakko Kogyo Co. Ltd. | Oxygen-containing heterocyclic compounds |
| CA2272327A1 (en) | 1996-11-19 | 1998-05-28 | Kyowa Hakko Kogyo Co., Ltd. | Oxygen-containing heterocyclic compounds |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| US6693116B2 (en) * | 2001-10-08 | 2004-02-17 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| JP4890439B2 (ja) | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| JP2007091597A (ja) * | 2005-09-27 | 2007-04-12 | Kyorin Pharmaceut Co Ltd | ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤 |
| US20090196284A1 (en) * | 2006-06-28 | 2009-08-06 | Nokia Siemens Networks Gmbh & Co.Kg | Method for Providing an Emergency Call Service for VoIP Subscribers |
| WO2008006540A1 (en) * | 2006-07-12 | 2008-01-17 | Syngenta Participations Ag | Triazolopyridine derivatives as herbicides |
| JP2008024599A (ja) * | 2006-07-18 | 2008-02-07 | Kyorin Pharmaceut Co Ltd | ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬 |
| JP2008069144A (ja) * | 2006-08-17 | 2008-03-27 | Kyorin Pharmaceut Co Ltd | ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| ES2380395T3 (es) * | 2007-04-16 | 2012-05-11 | Leo Pharma A/S | Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas |
| CA2692249A1 (en) | 2007-06-19 | 2008-12-24 | Yasushi Kohno | Pyrazolone derivative and pde inhibitor containing the same as active ingredient |
| WO2008156094A1 (ja) * | 2007-06-19 | 2008-12-24 | Kyorin Pharmaceutical Co., Ltd. | ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| JP2009040711A (ja) * | 2007-08-08 | 2009-02-26 | Kyorin Pharmaceut Co Ltd | カルボスティリル誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT |
| WO2010041711A1 (ja) | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
-
2009
- 2009-12-18 US US13/140,505 patent/US8952162B2/en not_active Expired - Fee Related
- 2009-12-18 BR BRPI0922452A patent/BRPI0922452A2/pt active Search and Examination
- 2009-12-18 NZ NZ593595A patent/NZ593595A/xx not_active IP Right Cessation
- 2009-12-18 JP JP2011541089A patent/JP5743901B2/ja not_active Expired - Fee Related
- 2009-12-18 CN CN200980156864.XA patent/CN102317287B/zh not_active Expired - Fee Related
- 2009-12-18 SI SI200931410A patent/SI2379548T1/sl unknown
- 2009-12-18 RS RS20160308A patent/RS54752B1/sr unknown
- 2009-12-18 WO PCT/DK2009/000262 patent/WO2010069322A1/en active Application Filing
- 2009-12-18 HU HUE09795687A patent/HUE027770T2/en unknown
- 2009-12-18 DK DK09795687.4T patent/DK2379548T3/en active
- 2009-12-18 RU RU2011129786/04A patent/RU2544011C2/ru active
- 2009-12-18 ES ES09795687T patent/ES2570769T3/es active Active
- 2009-12-18 MX MX2011006428A patent/MX2011006428A/es active IP Right Grant
- 2009-12-18 KR KR1020117016745A patent/KR20110094355A/ko not_active Application Discontinuation
- 2009-12-18 SG SG2011044203A patent/SG172206A1/en unknown
- 2009-12-18 EP EP09795687.4A patent/EP2379548B1/en active Active
- 2009-12-18 AU AU2009328752A patent/AU2009328752B2/en not_active Ceased
- 2009-12-18 CA CA2747022A patent/CA2747022A1/en not_active Abandoned
- 2009-12-18 PL PL09795687T patent/PL2379548T3/pl unknown
-
2011
- 2011-06-14 ZA ZA2011/04422A patent/ZA201104422B/en unknown
- 2011-06-15 IL IL213570A patent/IL213570A/en not_active IP Right Cessation
- 2011-06-17 NO NO20110871A patent/NO20110871A1/no not_active Application Discontinuation
-
2012
- 2012-06-25 HK HK12106184.9A patent/HK1165791A1/xx not_active IP Right Cessation
-
2014
- 2014-12-18 JP JP2014256695A patent/JP2015096535A/ja not_active Withdrawn
-
2016
- 2016-05-06 CY CY20161100373T patent/CY1117562T1/el unknown
- 2016-05-09 HR HRP20160488TT patent/HRP20160488T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20110871A1 (no) | 2011-09-19 |
| SI2379548T1 (sl) | 2016-06-30 |
| EP2379548A1 (en) | 2011-10-26 |
| HK1165791A1 (en) | 2012-10-12 |
| DK2379548T3 (en) | 2016-05-17 |
| HUE027770T2 (en) | 2016-11-28 |
| KR20110094355A (ko) | 2011-08-23 |
| IL213570A0 (en) | 2011-07-31 |
| NZ593595A (en) | 2013-07-26 |
| IL213570A (en) | 2015-10-29 |
| AU2009328752A1 (en) | 2011-07-07 |
| PL2379548T3 (pl) | 2016-08-31 |
| JP2012512192A (ja) | 2012-05-31 |
| AU2009328752B2 (en) | 2015-07-16 |
| HRP20160488T1 (hr) | 2016-06-17 |
| WO2010069322A1 (en) | 2010-06-24 |
| CN102317287B (zh) | 2014-10-08 |
| JP2015096535A (ja) | 2015-05-21 |
| US8952162B2 (en) | 2015-02-10 |
| CN102317287A (zh) | 2012-01-11 |
| SG172206A1 (en) | 2011-07-28 |
| MX2011006428A (es) | 2011-07-28 |
| ZA201104422B (en) | 2012-09-26 |
| JP5743901B2 (ja) | 2015-07-01 |
| RU2544011C2 (ru) | 2015-03-10 |
| CA2747022A1 (en) | 2010-06-24 |
| CY1117562T1 (el) | 2017-04-26 |
| EP2379548B1 (en) | 2016-03-09 |
| BRPI0922452A2 (pt) | 2015-12-15 |
| ES2570769T3 (es) | 2016-05-20 |
| US20120028974A1 (en) | 2012-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54752B1 (sr) | Triazolopiridini kao inhibitori fosfodiesteraze za lečenje kožnih bolesti | |
| CA2236677A1 (en) | 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinone derivatives, their preparation and their use as anti-bacterial agents | |
| MY161631A (en) | Herbicidal pyrimidone derivatives | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| UA100242C2 (uk) | Похідна оксопіразину, проміжні сполуки, гербіцид на основі похідної оксопіразину та спосіб боротьби з небажаною рослинністю | |
| WO2005037783A3 (fr) | Composes tricycliques comme inhibiteurs de transport de glycine | |
| GB0129476D0 (en) | Organic compounds | |
| TW200833690A (en) | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | |
| HRP20080113T3 (en) | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | |
| DE60318583D1 (de) | N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung | |
| TW200800949A (en) | Macrocylic inhibitors of hepatitis C virus | |
| MX2009011769A (es) | Derivados de piridona como inhibidores de mapk p38a. | |
| WO2005070924A8 (en) | Substituted quinolines and their use as mycobacterial inhibitors | |
| JOP20190239A1 (ar) | مركبات مثبطة لـ vmat2 وتركيبات منها | |
| MY183326A (en) | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | |
| HRP20080119T3 (en) | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| MY173664A (en) | Quinoline derivatives as antibacterial agents | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| AR041605A1 (es) | Compuesto 1- sustituido-4-nitroimidazol y metodo para preparar el mismo | |
| JO2837B1 (en) | Quinoline derivatives acting as antibacterial agents | |
| YU43902A (sh) | Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| TW200616679A (en) | Modified-release preparation | |
| DE69119135D1 (de) | Substituierte Pyridinsulfonamidverbindungen, diese enthaltende herbizide Zusammensetzungen und Verfahren zu ihrer Herstellung | |
| TW200735867A (en) | Medicine comprising substituted urea derivative | |
| MY139011A (en) | Piperazine compounds, a process for their preparation and pharmaceutical compositions containing them |